web analytics

FDA, Medical Device Makers & Wharton’s Healthcare Management Professors Matthew Grennan & Robert Town

FDA, Medical Device Makers & Wharton’s Healthcare Management Professors Matthew Grennan & Robert Town

July 6, 2015

Knowledge@Wharton recently ran a piece titled: Is the FDA too Tough on Medical Device Makers? The article is based off of a paper written by Wharton healthcare management professors Matthew Grennan and Robert Town,  Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices.”  

Grennan and Town looked at the medical device approval process and compared the United States to Europe (EU). They looked at second-generation cardiac stents and found the FDA was pretty close to optimal and EU was too lax regarding to market regulations.

In this paper, we’re examining the approach that the FDA takes to medical device regulation and asking the question: Is it optimal, or how close to optimal is it? There’s a raging debate about whether the FDA is too difficult on medical device regulation, whether it’s too hard for device manufactures to get their device through the regulatory process, or whether [the agency is] too lax and lets too many potentially harmful devices through the process.  There really is no other kind of similar analysis out there that’s been able to credibly identify the causal relationship between regulatory regimes and this information content, and the benefits that patients get from these devices.* So we think our research is kind of one of a kind. There’s some older research that’s related to what we did, but we think ours is pretty unique in that sense.

*There still isn’t. A crucial element that’s missing in Grennan and Town’s self-congratulatory paper is the lack of acknowledgement that most first to market medical devices are created at the startup level where a larger company acquires the startup and their technology.   As this site often points out startups operate under the guise they’re too small and off the radar of  theFDA where there’s a greater propensity to cut regulatory corners in order to show hypergrowth and sell to a larger company at the expense of patients, employees & taxpayers alike. Cutting regulatory corners and fraud are one in the same.  While Grennan & Town’s findings are interesting they’re not really relevant.

That surprised us — that the U.S. was so close to optimal, given the calls for reforms at the FDA. We kind of expected the FDA to be too difficult to get through.

The approval process for a medical device is known as a 510 (k) and once a device is approved all other similar devices (substantially equivalent) are approved based on that similarity and is what’s known a predicate device.  Grennan & Town studied second generation devices meaning all of the devices were predicate devices based on something that was previously approved & similar.

Substancially Equivalent Medical Devices Killing My Career

The FDA’s Substancially Equivalent Medical 510 (k), Medical Device Startups & The Sociopathic Business Model™

What appears isn’t addressed in their paper is what if company was fraudlent in the predicate device process  or if a predicate device is pulled by the FDA (or better still if after meeting with the FDA the company “decided” to pull the product off the market), then what happens to all the other devices that were approved off of a device that was either pulled by the FDA or by the company after meeting with the FDA? This is a tactic often used by the FDA to allow the company to save face publically but at what cost to the people if other devices remain?

Johnson & Johnson sold the Relieva Stratus MicroFlow Spacer for three years after they acquired startup Acclarent.

Johnson & Johnson sold the Relieva Stratus MicroFlow Spacer for three years after they acquired startup Acclarent.

Frequent readers of this site are familiar with my former employer medical device startup Acclarent which was acquired by Johnson & Johnson’s Ethicon for $785 million in January 2010; and, most recently the DOJ arrested & indicted two former executives on 18 counts of fraud (some related to the 510(k)) and there’s a case filed in CA stating that both Acclarent & Johnson & Johnson knowingly marketed its Relieva Stratus Microflow Spacer for an unapproved drug deliver use.

Chairman & CEO of Johnson & Johnson Alex Gorsky received his masters from The Wharton School of Business.

Alex Gorsky Chairman & CEO of Johnson & Johnson and Wharton Masters grad


Johnson & Johnson “decided” to stop selling the Relieva Stratus MicroFlow Spacer three full years after acquiring startup Acclarent

“You don’t have to get it 100% right. When you get it 60%, go! Any more time that you spend trying to figure it out, you’re going to lose in the speed that you’re missing out on.”

Chairman & CEO of Johnson & Johnson Alex Gorsky

Hopefully no other devices were approved where the Stratus MicroFlow Spacer was used as the predicate device; and,that first generation medical devices, because of increased regulatory fraud, are included in future studies addressing concerns over the FDA approval process and medical devices. The study only needs to look to Wharton grad Alex Gorsky’s own words to know that greed and fraud are relevant and in part what makes  Grennan & Town’s study not relevant.

Digging deeper:

It’s always important to note where the money comes from to fund studies. Remember Congress created non-profit Reagan-Udall Foundation for the FDA 2009 – 2013 where much of the revenue was generated by Big Pharma’s DOJ federal offenders which is a conflict of interest.

Top 10 Big Pharma DOJ Fines  vs Advertising Dollars 2014 Killing My Career

These pharma/device companies paid huge advertising dollars, huge DOJ fines and contributed to Congress created non-profit Reagan-Udall Foundation.

Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices

Matthew Grennan, Robert Town

NBER Working Paper No. 20981
Issued in February 2015

—- Acknowledgements —–

Data for this research was provided by Millennium Research Group . We owe thanks to Jason Abaluck, Andres Aradillas-Lopez, Steve Berry, Joe Harrington, Robin Lee, Scott Stern, and audiences at the BEA, Chicago, Clemson, FTC, HEC Montreal Summer IO Conference, iHEA, Johns Hopkins, Kellogg Conference on Healthcare Markets, Minnesota, NBER IO and Health Care Summer Institutes, NUS, Ohio State, Penn State, Rice/Houston, UCLA, Wharton, and Yale for helpful comments. The University of Toronto, Wharton Dean’s Research Fund and Mack Center for Innovation, and the Indian School of Business provided financial assistance. Ellie Prager, Mike Punzalan, Emi Terasawa, and Christine Yang provided excellent research assistance. Any errors are our own. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

No Comments

Post a Comment